Clinical Trials
6 trialsNCT00086528 2022-05-13
Safety and Pharmacokinetics of XL647 Administered Orally to Subjects With Solid Tumors
Kadmon Corporation, LLC
Phase 1 Completed
NCT00336765 2022-05-13
Study of XL647 Administered Orally Daily to Patients With Solid Tumors
Kadmon Corporation, LLC
Phase 1 Completed
NCT00364780 2022-05-13
Study of XL647 in Subjects With Non-Small-Cell Lung Cancer
Kadmon Corporation, LLC
Phase 2 Completed
NCT00522145 2022-05-13
Study of XL647 in Subjects With NSCLC Who Have Progressed After Responding to Treatment With Gefitinib or Erlotinib
Kadmon Corporation, LLC
Phase 2 Completed
NCT02616393 2022-03-16
Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal Metastases
Kadmon Corporation, LLC
Phase 2 Completed
NCT02844439 2021-09-22
Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma
Kadmon Corporation, LLC
Phase 2 Completed